Transforming growth factor-beta potentiates vitamin D3-induced terminal monocytic differentiation of human leukemic cell lines.
We have investigated the effects of 1,25-dihydroxyvitamin D3 (D3) and/or transforming growth factor (TGF)-beta on one monocytic (U-937) and two human promyelocytic (HL-60 and AML-193) leukemic cell lines. D3 addition induces a partial monocytic maturation of the cell lines, whereas TGF-beta treatment is largely ineffective. Combined treatment with TGF-beta and D3 causes terminal monocytic maturation, as evaluated both by assessment of a large spectrum of membrane Ag and by functional assays. Furthermore, sequential addition of the two inducers showed that pretreatment with TGF-beta 1 followed by incubation with D3, but not vice versa, induces monocytic maturation as effectively as simultaneous treatment with both agents. In liquid culture the proliferative activity of these cell lines is slightly decreased by D3 and virtually unaffected by TGF-beta, whereas combined treatment with D3 and TGF-beta induces a markedly potentiated inhibitory effect. Furthermore, TGF-beta/D3 treatment (but not D3 alone) elicits the expression of membrane CD14, FcRI, FcRII, CD11a, CD11b, CD11c, ICAM-1, and PECAM-1 Ag at a level comparable to that observed on normal human monocytes. It is noteworthy that several of these Ag play an important role in monocyte physiology (e.g., CD14 Ag mediates the binding of bacterial LPS to monocytes). Treatment with both TGF-beta and D3 (but not D3 alone) induces superoxide anions and H2O2 production similar to that of circulating monocytes. In semisolid culture, D3 and TGF-beta alone cause, respectively, a marked and slight loss of cloning efficiency of the cell lines, whereas their combined addition synergistically results in a complete loss of the cloning capacity. These findings suggest a physiologic role for TGF-beta in monocyte maturation. Furthermore, they may pave the way to the design of clinical protocols combining D3 and TGF-beta in the differentiation therapy of acute promyelocytic/myelomonocytic leukemia.
Department of Hematology and Oncology, Istituto Superiore di Sanità, Rome, Italy.
U
U
Testa
R
R
Masciulli
E
E
Tritarelli
R
R
Pustorino
G
G
Mariani
R
R
Martucci
T
T
Barberi
A
A
Camagna
M
M
Valtieri
C
C
Peschle
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000954:Antigens, Surface / Q000187:drug effects; D015815:Cell Adhesion Molecules / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002762:Cholecalciferol / Q000494:pharmacology*; D016207:Cytokines / Q000096:biosynthesis / Q000187:drug effects; D004357:Drug Synergism; D006801:Humans; D006861:Hydrogen Peroxide / Q000378:metabolism; D007938:Leukemia / Q000378:metabolism / Q000473:pathology*; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D009580:Nitroblue Tetrazolium / Q000378:metabolism; D011961:Receptors, Fc / Q000187:drug effects; D013481:Superoxides / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D000276:Adjuvants, Immunologic; D000954:Antigens, Surface; D015815:Cell Adhesion Molecules; D016207:Cytokines; D011961:Receptors, Fc; D016212:Transforming Growth Factor beta; D013481:Superoxides; D002762:Cholecalciferol; D009580:Nitroblue Tetrazolium; D006861:Hydrogen Peroxide